- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04630353
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation
Study Overview
Status
Intervention / Treatment
Detailed Description
The window of opportunity, Study H-200-002, will examine the effects of study agent (HB-201) on subjects during the "window" between diagnosis of their cancer and their definitive cancer surgery or chemoradiation.
The study will be a 2-arm study design. In Arm 1, the study will enroll subjects with resectable stage I-III human papillomavirus 16 positive (HPV 16+) genotype squamous cell cancer of the oropharynx or unknown primary cancer site who are candidates for transoral surgery. Participants will receive a single intravenous dose of the study agent HB-201 prior to transoral surgery administered intravenously.
In Arm 2, the study will enroll cervical cancer subjects who have histologically confirmed newly diagnosed advanced squamous cell carcinoma, adenocarcinoma, and/ or adenosquamous cell carcinoma with HPV 16+ genotype clincal stages IB to IVB with plan for initial treatment of definitive chemoradiation. Participants will receive a single intravenous dose of HB-201 prior to the start of chemoradiation.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: General Hookipa Contact
- Phone Number: 1-866-544-8544
- Email: hookipa@careboxhealth.com
Study Contact Backup
- Name: Backup Hookipa Contact
- Email: clinicaltrials@hookipapharma.com
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Hospital and the Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All subjects:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Confirmed HPV 16+ (human papilloma virus 16 positive) genotype testing of cancer.
- Disease-free for ≥ 2 years from other curatively treated cancers, with protocol-defined exceptions.
- Evaluated by cardiologist and/or neurologist if protocol-defined cardiac or neurological event within the last 6 months.
HPV 16+ Oropharynx Cancer
- Newly diagnosed, head and neck squamous cell carcinoma or undifferentiated carcinoma of the oropharynx origin or unknown primary cancer site, determined to be resectable.
- AJCC v8.0 Tumor, Node, Metastasis (TNM) stage I-III, cT0- T3, and cervical nodes N1-N3 based on clinical or radiographic criteria with no evidence of distant metastases.
- No prior radiation above the clavicles.
- Must have acceptable renal and hepatic function as defined per protocol.
HPV 16+ Cervical Cancer (Arm 2)
- Newly diagnosed, histologically confirmed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma): International Federation of Gynecology and Obstetrics (FIGO) clinical stages IB to IVB with plan for initial treatment of definitive chemoradiation (platinum agent weekly with radiotherapy) for either curative intent or control of local (pelvic) disease.
- No prior radiation to the abdomen or pelvis.
- Must have a safe and accessible tumor lesion amenable for biopsy.
- Must have normal organ and marrow function as defined per protocol.
- Must not have a known allergy to cisplatin, carboplatin, or compounds of similar biologic composition.
Exclusion Criteria:
All subjects:
- Treatment with any systemic anticancer therapy within 3 years (unless agreed otherwise between the Sponsor and the Investigator).
- Treatment with any chronic immunosuppressive medication within 6 months (unless agreed otherwise between the Sponsor and Investigator).
- Uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension.
- Live vaccine within 28 days (unless agreed otherwise between Sponsor and Investigator).
- Known diagnosis of acquired immunodeficiency syndrome (AIDS).
- Positive Hepatitis B or Hepatitis C tests indicating acute or chronic infection.
- Intercurrent illness likely to interfere with protocol therapy.
- Female subjects who are pregnant or breastfeeding.
- Female subjects of childbearing potential who do not agree to the use of highly effective contraception per protocol.
- Male subjects with sexual partners of childbearing potential who do not agree to the use of protocol-defined contraception
HPV 16+ Oropharynx Cancer (Arm 1)
• Primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical spine.
HPV 16+ Cervical Cancer (Arm 2)
- Treatment with chemotherapy for cervical cancer, prior to planned chemoradiation.
- Prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HB-201 Intravenously on Day 1
Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx or unknown primary cancer site.
|
HB-201 given IV, one (1) time, on day 1.
HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
|
Experimental: HB-201 Intravenously 7 to 14 days before chemoradiation
Patients with newly diagnosed HPV 16+ genotype advanced cervical cancer, clinical stages IB to IVB with plan for initial treatment of definitive chemoradiation.
|
HB-201 given IV, one (1) time, on day 1.
HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer.
Time Frame: Approximately 6-8 weeks
|
Measurement of antigen-specific CD8+ T cells in blood and tissue (E7E6 antigen specific assay).
|
Approximately 6-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical evidence of response to HB-201
Time Frame: Approximately 6-8 weeks
|
Change in tumor size per RECIST v1.1
|
Approximately 6-8 weeks
|
Toxicity profile of HB-201
Time Frame: Approximately 30 days post HB-201 administration
|
Number and type of adverse events per CTCAE v5.0
|
Approximately 30 days post HB-201 administration
|
Assessment of gene expression and tumor mutational burden (TMB, MSI) in tumor specimens.
Time Frame: Approximately 6-8 weeks
|
Pre and post administration of HB-201
|
Approximately 6-8 weeks
|
Investigate metabolic and proteomics changes in serum and plasma.
Time Frame: Approximately 6-8 weeks
|
Pre and post administration of HB-201
|
Approximately 6-8 weeks
|
Investigate the t-cell receptor repertoire diversity and clonality.
Time Frame: Approximately 6-8 weeks
|
Pre and post administration of HB-201.
|
Approximately 6-8 weeks
|
Other Exploratory Biomarker research may be conducted on any tumor tissue and/or blood samples collected during the study.
Time Frame: Approximately 6-8 weeks
|
Approximately 6-8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chief Medical Officer, Hookipa Biotech GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Oropharyngeal Neoplasms
Other Study ID Numbers
- H-200-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
-
Gilead SciencesTerminatedHuman Papillomavirus (HPV) 16+ Relapsed/Refractory CancerUnited States
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...PapiVax Biotech, Inc.RecruitingHPV 16+ Recurrent or Metastatic CancerUnited States
-
Hospital General de México Dr. Eduardo LiceagaUnknownHPV DNA | Human Papillomavirus (HPV)-Related Cervical CancerMexico
-
University Hospital, BrestCompletedCervical Cancer | Vaccine Preventable Disease | HPV | HPV Vaccination | Cervical LesionFrance
-
Teal Health, Inc.Enrolling by invitationHPV Infection | HPV 16 Infection | Hpv | High Risk HPVUnited States
-
Icahn School of Medicine at Mount SinaiActive, not recruitingLocally Advanced HPV Positive Oropharynx CancerUnited States
-
Miquel Angel Pavon RibasCatalan Institute of Health; Hospital del MarRecruitingCervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18Spain
-
GenticelPPDTerminatedHPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSILUnited States
-
Christian HinrichsRecruitingCervical Cancer | HPV-Related Malignancy | Metastatic Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditionsUnited States
Clinical Trials on HB-201 IV
-
Hookipa Biotech GmbHRecruitingHPV-Related Squamous Cell CarcinomaUnited States, Spain, Netherlands
-
University of ChicagoRecruitingHead and Neck Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | HPV | Human Papilloma VirusUnited States
-
Johnson & Johnson Pte LtdShanghai China-Norm Management Consulting co.,LTD; Shanghai Skin Disease HospitalCompleted
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonActive, not recruiting
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableParkinson DiseaseUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availablePost COVID-19 SyndromeUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableAmyotrophic Lateral SclerosisUnited States
-
Hope Biosciences Stem Cell Research FoundationNo longer available
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonNo longer availableSpinal Cord Injury at C5-C7 LevelUnited States
-
Hookipa Biotech GmbHCentre for Vaccinology Ghent - CEVACCompletedCytomegalovirus InfectionBelgium